Synthesis and Evaluation of New Pyrazoline Derivatives as Potential Anticancer Agents in HepG-2 Cell Line
Open Access
Abstract
Cancer is a major public health concern worldwide. Adverse effects of cancer treatments still compromise patients’ quality of life. To identify new potential anticancer agents, a series of novel pyrazoline derivatives were synthesized and evaluated for cytotoxic effects on HepG-2 (human liver hepatocellular carcinoma cell line) and primary hepatocytes. Compound structures were confirmed by 1H-NMR, mass spectrometry, and infrared imaging. An in vitro assay demonstrated that several compounds exerted cytotoxicity in the micromolar range. Benzo[b]thiophen-2-yl-[5-(4-hydroxy-3,5-dimethoxy-phenyl)-3-(2-hydroxy-phenyl)-4,5-dihydo-pyrazol-1-yl]-methanone (b17) was the most effective anticancer agent against HepG-2 cells owing to its notable inhibitory effect on HepG-2 with an IC50 value of 3.57 µM when compared with cisplatin (IC50 = 8.45 µM) and low cytotoxicity against primary hepatocytes. Cell cycle analysis and apoptosis/necrosis evaluation using this compound revealed that b17 notably arrested HepG-2 cells in the G2/M phase and induced HepG-2 cells apoptosis. Our findings indicate that compound b17 may be a promising anticancer drug candidate.Keywords
Funding Information
- Guangdong Natural Science Foundation of China (9351503102000001)
This publication has 29 references indexed in Scilit:
- Molecular aspects of cancer cell resistance to chemotherapyBiochemical Pharmacology, 2013
- Cytotoxic and apoptotic effects of chalcone derivatives of 2‐acetyl thiophene on human colon adenocarcinoma cellsCell Biochemistry and Function, 2012
- MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemiaLeukemia, 2012
- Synthesis of some new 1,3,5-trisubstituted pyrazolines bearing benzene sulfonamide as anticancer and anti-inflammatory agentsBioorganic & Medicinal Chemistry Letters, 2011
- Phase II trial of pyrazoloacridine (NSC#366140) in patients with metastatic breast cancerInvestigational New Drugs, 2009
- MicroRNAs and cancer: An overviewCell Cycle, 2008
- 4507 ORAL Axitinib (AG-013736; AG) in patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sorafenibEuropean Journal of Cancer Supplements, 2007
- Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activityMolecular Cancer Therapeutics, 2007
- Phase 2 Studies of Sunitinib and AG013736 in Patients with Cytokine-Refractory Renal Cell CarcinomaClinical Cancer Research, 2007
- BIRB796 Inhibits All p38 MAPK Isoforms in Vitro and in VivoJournal of Biological Chemistry, 2005